What is the current recommended treatment for PE?
Anticoagulation therapy is the primary treatment option for most patients with acute PE. The utilization of factor Xa antagonists and direct thrombin inhibitors, collectively termed Novel Oral Anticoagulants (NOACs) are likely to increase as they become incorporated into societal guidelines as first line therapy.
Should Subsegmental PE be treated?
A leading specialty society advises that patients with subsegmental PE without deep venous thrombosis receive anticoagulation if the risk of recurrence is high, and surveillance if recurrence risk is low.
Can tPA be given for PE?
The MOPPETT trial demonstrated that half-dose thrombolytics (50 mg tPA) might safely reduce the rate of recurrent PE and late-onset pulmonary hypertension in intermediate risk pulmonary embolism.
What thrombolytics are used for PE?
Currently, three agents are approved by the U.S. Food and Drug Administration (FDA) for use in PE thrombolysis (Table 2): streptokinase (Streptase), urokinase (Abbokinase) and recombinant tissue plasminogen activator (rtPA).
When do you give tPA for MI?
FDA-approved indications for alteplase include pulmonary embolism, myocardial infarction with ST-segment elevation (STEMI), ischemic stroke when given within 3 hours of the start of symptoms, and re-establishment of patency in occluded intravenous (IV) catheters.
What does Submassive PE mean?
Submassive (or intermediate-risk) PE refers to those patients with acute PE without systemic hypotension but with evidence of either right ventricle (RV) dysfunction or myocardial necrosis.
What thrombolytics are used for pulmonary embolism?
Alteplase (rt-PA) is still the most commonly used thrombolytic agent in pulmonary embolism. The approved dose for PTE is infusion of 100 mg in 2 hours. This dose is known to cause major bleeding complications (primarily cerebral hemorrhage), especially in older patients.
How much heparin is given for pulmonary embolism?
Heparin in a fixed low dose of 5000 U SC every 8 or 12 hours is an effective and safe form of prophylaxis in medical and surgical patients at risk of venous thromboembolism. Low-dose heparin reduces the risk of venous thrombosis and fatal PE by 60% to 70%.
What is a Submassive PE?
What is the management of submassive and massive PE?
Management of submassive and massive PE often involves clinicians from multiple specialties, which can potentially delay the development of a unified treatment plan. In addition, patients with submassive PE can deteriorate after their presentation and require escalation of care.
What is intermediate PE (submassive PE)?
Any patient with a positive sPESI score falls into the intermediate-risk PE category (equivalent to submassive PE in the AHA/ACCP classifications). ESC guidelines further risk stratify intermediate PE (submassive PE) into intermediate low risk and intermediate high risk ( Table 1 ). Table 1.
What are the treatment options for massive acute pulmonary embolism (PE)?
Treatment of massive acute pulmonary embolism: the use of low doses of intrapulmonary arterial streptokinase combined with full doses of systemic heparin. Chest. 1988; 93: 234–240. Crossref Medline Google Scholar 28 Gonzalez-Juanatey JR, Valdes L, Amaro A, Iglesias C, Alvarez D, Garcia Acuna JM, de la Pena MG.
What is the role of Fibrinolysis in the treatment of submassive PE?
Fibrinolysis functions as a “medical embolectomy” and, when successful, will rapidly reverse hemodynamic compromise and gas-exchange derangements. In patients with submassive PE, fibrinolysis relieves RV pressure overload and may avert impending hemodynamic collapse and death due to progressive RV failure.